Dec 10 (Reuters) - Biomea Fusion Inc BMEA.O:
BIOMEA FUSION ANNOUNCES PRELIMINARY DATA FROM ONGOING COVALENT-103 STUDY OF INVESTIGATIONAL COVALENT FLT3 INHIBITOR BMF-500 IN RELAPSED OR REFRACTORY ACUTE LEUKEMIA
BIOMEA FUSION INC - BMF-500 SHOWS FAVORABLE SAFETY PROFILE WITH NO DOSE-LIMITING TOXICITIES
BIOMEA FUSION INC - PRELIMINARY DATA SUPPORTS BMF-500 AS TRANSFORMATIVE THERAPY FOR FLT3 MUTATED R/R ACUTE LEUKEMIA
Source text: nGNX3rq5pv
Further company coverage: BMEA.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.